Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer

Hoff, Paulo M.; Saad, Everardo D.; Pazdur, Richard; Wolff, Robert A.; Lassere, Yvonne; Bogaard, K. R.; Abbruzzese, James L.

doi:10.1023/b:drug.0000026257.31142.41

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of irinotecan (175‐200 mg/m 2 per dose) with oxaliplatin (85‐130 mg/m 2 per dose) every 3 weeks51, 52 or of irinotecan (50 mg/m 2 per dose) with oxaliplatin (60 mg/m 2 per dose) weekly33 has been tolerated well in adults. The novel schedule studied here in children did not prove feasible.…”

Section: Discussionmentioning

confidence: 99%

A functional polymorphism in the catechol‐O‐methyltransferase gene is associated with osteoarthritis‐related pain

Meurs¹,

Uitterlinden²,

Stolk³

et al. 2009

Arthritis & Rheumatism

View full text Add to dashboard Cite

The separability between overall and internal motions is evaluated over multiple folding trajectories of the villin headpiece subdomain. The analysis, which relies on the Prompers‐Brüschweiler separability index, offers a potentially useful perspective on protein folding. The protein is considered folded in this study, not when it reaches some static target, but rather when it tumbles as a dynamically constrained object. The analysis also demonstrates how the separability index, when applied to protein folding simulations, can facilitate the analysis of NMR relaxation data. Proteins 2012;. © 2012 Wiley Periodicals, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

A functional polymorphism in the catechol‐O‐methyltransferase gene is associated with osteoarthritis‐related pain

Meurs¹,

Uitterlinden²,

Stolk³

et al. 2009

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…The combination of irinotecan (175–200 mg/m 2 /dose) with oxaliplatin (85–130 mg/m 2 /dose) every 3 weeks51,52 or of irinotecan (50 mg/m 2 /dose) with oxaliplatin (60 mg/m 2 /dose) weekly33 has been well-tolerated in adults. The novel schedule studied here in children did not prove feasible.…”

Section: Discussionmentioning

confidence: 99%

Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors

McGregor

Spunt

Furman

et al. 2009

Cancer

View full text Add to dashboard Cite

BACKGROUND:For this report, the authors estimated the maximum tolerated dose (MTD) and investigated the toxicities of oxaliplatin combined with irinotecan in children with refractory solid tumors.METHODS:Oxaliplatin was administered on Days 1 and 8 in combination with irinotecan on Days 1 through 5 and Days 8 through 12 of a 21‐day cycle. An oral cephalosporin was administered daily to ameliorate irinotecan‐associated diarrhea. Pharmacokinetic studies of oxaliplatin and uridine diphosphate glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) genotyping were performed.RESULTS:Thirteen patients were enrolled. Dose‐limiting diarrhea (n = 3), serum lipase elevation (n = 3), serum amylase elevation (n = 2), colitis, abdominal pain, and headache (n = 1 each) occurred at the first dose level (oxaliplatin at a dose of 60 mg/m2; irinotecan at a dose of 20 mg/m2). Only 1 of 7 patients who received reduced doses of both agents (40 mg/m2/dose oxaliplatin; 15 mg/m2/dose irinotecan) experienced a dose‐limiting toxicity (DLT): diarrhea. When the oxaliplatin dose was re‐escalated (60 mg/m2) with irinotecan at a dose of 15 mg/m2, 2 of 3 patients had a DLT (1 episode of diarrhea, 1 episode of hypokalemia). Myelosuppression was minimal. One patient had a complete response, and another patient had stable disease for 6 cycles of therapy. The median oxaliplatin area under the concentration versus time curve (AUC0→∞) was 5.9 μg · hour/mL (range, 1.8‐7.6 μg · hour/mL). The frequency of the 6/6, 6/7, and 7/7 UGT1A1 promoter genotypes was 5 of 10, 4 of 10, and 1 of 10, respectively.CONCLUSIONS:The oxaliplatin MTD was 40 mg/m2 per dose on Days 1 and 8 in combination with irinotecan 15 mg/m2 per dose on Days 1‐5 and Days 8‐12. There was some evidence of antitumor activity; however, severe toxicity, both expected (diarrhea) and unexpected (elevation in pancreatic enzymes), was observed. Cancer 2009. © 2009 American Cancer Society.

show abstract

Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer

Hoff

Wolff

Xiong

et al. 2006

Cancer

Self Cite

View full text Add to dashboard Cite

Electrically conducting composites based on polyaniline and polyacrylonitrile were prepared by two slightly different techniques and were characterized by Fourier transform infrared spectroscopy and scanning electron microscopy. The thermooxidative degradation of the composites was studied by simultaneous thermogravimetric analysis and differential thermal analysis techniques. The stability of the composites in terms of direct‐current electrical conductivity retention was studied in an oxidative environment by isothermal and cyclic techniques. The composites were thermally stable under ambient environmental conditions; however, their properties were dependent on the method of preparation. © 2005 Wiley Periodicals, Inc. J Appl Polym Sci 99: 437–448, 2006

show abstract

Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer

Cited by 4 publications

References 21 publications

A functional polymorphism in the catechol‐O‐methyltransferase gene is associated with osteoarthritis‐related pain

A functional polymorphism in the catechol‐O‐methyltransferase gene is associated with osteoarthritis‐related pain

Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors

Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer

Contact Info

Product

Resources

About